Cervicomedullary hemangioblastoma treated with bevacizumab

Mak, Gloria; Algird, Almunder; Greenspoon, Jeffrey; Provias, John; Hirte, Hal W.

doi:10.1093/noajnl/vdaa076

Cited by 2 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Theoretically, agents like bevacizumab can inhibit VEGF, disrupting the blood supply crucial for tumor growth [75]. A case study involving a man with surgically unresectable cervical cord HB, leading to quadriparesis, demonstrated significant tumor regression on follow-up MRI imaging after undergoing treatment with bevacizumab [76]. In a separate case, a female patient initially underwent an unsuccessful tumor reduction surgery and was subsequently prescribed dexamethasone and SRS.…”

Section: Emerging Hb Treatmentsmentioning

confidence: 99%

See 1 more Smart Citation

Emerging therapies of hemangioblastomas

Sanghadia,

Martinez,

McNulty

et al. 2023

Explor Neurosci

View full text Add to dashboard Cite

Hemangioblastoma are benign, vascularized cranial tumors caused by autosomal dominant inherited von Hippel-Lindau disease or can appear sporadically. This review will investigate current and emerging treatments for cerebral tumors. It will focus on the current and, more importantly, developing hemangioblastoma treatments. Surgical resectioning and radiotherapy are effective treatment options for cerebral tumors, whereas chemotherapies are not commonly used due to their limited ability to penetrate the blood-brain barrier. Recent chemotherapies have shown promise, but further research is needed to determine the efficacy as a treatment for hemangioblastomas. New advances in brachytherapy and immunotherapy are considered promising treatment options for hemangioblastoma. This review aims to offer valuable insights into the latest developments in hemangioblastoma treatments.

show abstract

Section: Emerging Hb Treatmentsmentioning

confidence: 99%

“…β-Antagonists like ICI-118,551 and PT2385, are alternative therapies that exhibit anti-angiogenic properties and disrupt tumor metastasis [78,79]. Novel immunotherapies like bevacizumab can also treat HBs and have been shown to improve the quality of life for patients [75,76,81].…”

Section: Summary Of Existing and Novel Hb Treatmentsmentioning

confidence: 99%

Emerging therapies of hemangioblastomas

Sanghadia,

Martinez,

McNulty

et al. 2023

Explor Neurosci

View full text Add to dashboard Cite

show abstract

“…In some cases, due to the clinical state of the patient or the localization of the tumor, surgical intervention cannot be achieved. In 2020, Mak et al [18] published the case of an immunocompetent patient that presented with a one-year history of progressive nausea and vomiting. After an MRI scan, a homogeneous enhancing intra-axial mass located at cervicomedullary junction was revealed.…”

Section: Onementioning

confidence: 99%

Cervicomedullary junction intramedullary hemangioblastoma

Popescu,

Paslaru,

Gheorghiu

et al. 2022

roneuro

View full text Add to dashboard Cite

Hemangioblastoma is a rare, benign, highly vascularized tumour, that usually presents a muriform nodule. The most frequent localization is the posterior cranial fossa. The frequency of this spinal lesion is very low, representing less than 5% of spinal cord tumours. The presentation of hemangioblastoma can widely vary, from a solid tumour to a lesion with a cystic component. We present the case of a 43 years old patient, admitted to our clinic for left hemiparesis, swallowing disorders, and dysphonia. An MRI is performed and it showed a cervicomedullary junction tumour with a solid nodule and an anterior cystic cavity pushing towards the 4th ventricle. The patient underwent surgery for the total removal of the tumour. Post-operative CT confirmed the total ablation of the tumour. The patient is discharged with improved symptomatology. In the last 10 years, in our clinic were admitted 23 cases of hemangioblastoma, 14 males (61% of the patients) and 9 females (39%) with an age at presentation varied from 14 to 78 years (mean 48,2 years). Only 3 patients (13%) out of the 23 had associated von Hippel–Lindau syndrome, with hemangioblastomas also present in other locations. The most common location was the posterior fossa, in 13 cases (56,6%). Headache (69,5%), ataxia (56%) and balance disorders (52%) were the most common symptoms accused by patients. The follow-up varied from 6 to 84 months (mean 20 months). Only one patient died during hospitalization and one tumour recurrence was noted. Most patients improved or remained clinically stable postoperatively.

show abstract

Cervicomedullary hemangioblastoma treated with bevacizumab

Cited by 2 publications

References 12 publications

Emerging therapies of hemangioblastomas

Emerging therapies of hemangioblastomas

Cervicomedullary junction intramedullary hemangioblastoma

Contact Info

Product

Resources

About